PT946175E - Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais - Google Patents

Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais

Info

Publication number
PT946175E
PT946175E PT97945135T PT97945135T PT946175E PT 946175 E PT946175 E PT 946175E PT 97945135 T PT97945135 T PT 97945135T PT 97945135 T PT97945135 T PT 97945135T PT 946175 E PT946175 E PT 946175E
Authority
PT
Portugal
Prior art keywords
glucocorticiod
nasa
atpase
polls
inhibitors
Prior art date
Application number
PT97945135T
Other languages
English (en)
Portuguese (pt)
Inventor
Jan Trofast
Per Lindberg
Joan Pinas-Masso
Jordi Jorra-Carreras
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT946175E publication Critical patent/PT946175E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PT97945135T 1996-10-11 1997-10-01 Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais PT946175E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment

Publications (1)

Publication Number Publication Date
PT946175E true PT946175E (pt) 2003-04-30

Family

ID=20404214

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97945135T PT946175E (pt) 1996-10-11 1997-10-01 Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais

Country Status (33)

Country Link
EP (1) EP0946175B1 (cg-RX-API-DMAC7.html)
JP (1) JP4100713B2 (cg-RX-API-DMAC7.html)
KR (1) KR100510812B1 (cg-RX-API-DMAC7.html)
CN (1) CN1146416C (cg-RX-API-DMAC7.html)
AR (1) AR008886A1 (cg-RX-API-DMAC7.html)
AT (1) ATE230597T1 (cg-RX-API-DMAC7.html)
AU (1) AU738310B2 (cg-RX-API-DMAC7.html)
BR (1) BR9711896A (cg-RX-API-DMAC7.html)
CA (1) CA2268305C (cg-RX-API-DMAC7.html)
CZ (1) CZ298799B6 (cg-RX-API-DMAC7.html)
DE (1) DE69718347T2 (cg-RX-API-DMAC7.html)
DK (1) DK0946175T3 (cg-RX-API-DMAC7.html)
EE (1) EE04043B1 (cg-RX-API-DMAC7.html)
ES (1) ES2188995T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0000036A3 (cg-RX-API-DMAC7.html)
ID (1) ID23692A (cg-RX-API-DMAC7.html)
IL (1) IL129324A0 (cg-RX-API-DMAC7.html)
IS (1) IS1930B (cg-RX-API-DMAC7.html)
MY (1) MY117918A (cg-RX-API-DMAC7.html)
NO (1) NO321007B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ334786A (cg-RX-API-DMAC7.html)
PL (1) PL190902B1 (cg-RX-API-DMAC7.html)
PT (1) PT946175E (cg-RX-API-DMAC7.html)
RS (1) RS49599B (cg-RX-API-DMAC7.html)
RU (1) RU2197966C2 (cg-RX-API-DMAC7.html)
SA (1) SA97180641B1 (cg-RX-API-DMAC7.html)
SE (1) SE9603725D0 (cg-RX-API-DMAC7.html)
SK (1) SK284252B6 (cg-RX-API-DMAC7.html)
TR (1) TR199900770T2 (cg-RX-API-DMAC7.html)
TW (1) TW568784B (cg-RX-API-DMAC7.html)
UA (1) UA59374C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998016228A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA978842B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
EP1119349B1 (en) 1998-08-18 2008-07-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
NZ514442A (en) * 1999-03-03 2003-08-29 Optinose As Nasal delivery device
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
WO2003075926A1 (en) * 2002-03-14 2003-09-18 Altana Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
NZ536918A (en) * 2002-05-07 2006-09-29 Altana Pharma Ag Combination of pantoprazole and a respiratory agent for the treatment of respiratory diseases
WO2003094967A2 (en) * 2002-05-07 2003-11-20 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005025578A1 (en) 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
RU2252025C1 (ru) * 2003-11-28 2005-05-20 Дальневосточный государственный медицинский университет Способ лечения избыточной грануляционной ткани гортани и трахеи
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Also Published As

Publication number Publication date
SK38499A3 (en) 2000-03-13
ES2188995T3 (es) 2003-07-01
PL332692A1 (en) 1999-09-27
MY117918A (en) 2004-08-30
CZ122999A3 (cs) 1999-09-15
BR9711896A (pt) 1999-08-24
UA59374C2 (uk) 2003-09-15
NO991619L (no) 1999-04-06
CN1146416C (zh) 2004-04-21
DK0946175T3 (da) 2003-03-17
WO1998016228A1 (en) 1998-04-23
ATE230597T1 (de) 2003-01-15
CA2268305C (en) 2006-11-28
ZA978842B (en) 1998-04-14
SK284252B6 (sk) 2004-12-01
DE69718347T2 (de) 2003-08-28
HUP0000036A3 (en) 2003-02-28
JP4100713B2 (ja) 2008-06-11
NZ334786A (en) 2000-12-22
EP0946175A1 (en) 1999-10-06
JP2001508034A (ja) 2001-06-19
IS5021A (is) 1999-04-08
PL190902B1 (pl) 2006-02-28
CN1232397A (zh) 1999-10-20
RU2197966C2 (ru) 2003-02-10
YU16399A (sh) 2000-03-21
CA2268305A1 (en) 1998-04-23
SA97180641B1 (ar) 2005-12-18
NO991619D0 (no) 1999-04-06
AU4640997A (en) 1998-05-11
AR008886A1 (es) 2000-02-23
DE69718347D1 (de) 2003-02-13
HUP0000036A2 (hu) 2002-05-29
IL129324A0 (en) 2000-02-17
CZ298799B6 (cs) 2008-02-06
HU0000036D0 (cg-RX-API-DMAC7.html) 2002-05-29
KR100510812B1 (ko) 2005-08-31
ID23692A (id) 2000-05-11
KR20000049046A (ko) 2000-07-25
IS1930B (is) 2004-05-18
TW568784B (en) 2004-01-01
NO321007B1 (no) 2006-02-27
EE04043B1 (et) 2003-06-16
AU738310B2 (en) 2001-09-13
EE9900118A (et) 1999-10-15
HK1022848A1 (en) 2000-08-25
RS49599B (sr) 2007-06-04
SE9603725D0 (sv) 1996-10-11
EP0946175B1 (en) 2003-01-08
TR199900770T2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
EP1283702A4 (en) MEDICAL ASSOCIATION ARRANGEMENT AND METHOD OF THE APPLICATION
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
IL205242A0 (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
EP0833914A4 (en) BETA-11 HUMAN CHEMOKINE AND ALPHA-1 HUMAN CHEMOKINE
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
AP2002002393A0 (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
EE9900118A (et) H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
DE69709876D1 (de) Kieferorthopädische und parodontologische vorrichtungen
ZA977606B (en) Antimicrobial medical devices and methods of production and use.
GB9922752D0 (en) Medical devices and treatment and prophylaxis
DE69932577D1 (de) Stangenbehandlungsgerät und Stangenladegerät
DE60003550D1 (de) Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung
IS4452A (is) Bísýklískar amidínafleiður sem eru gagnlegar við læknismeðhöndlun
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
GB9802542D0 (en) New use
AU6091299A (en) Treatment device, treatment bed to be used therein and the use thereof
AU3061199A (en) Skin treatment compositions and the use thereof
GB9603657D0 (en) Improvements in the treatment of vaginal infections
IL143795A0 (en) Use of 3-isoxazolidinones and hydroxylamic acids for the treatment of infections